CD8A and non-small cell lung carcinoma: For example, hydroxychloroquine (HCQ) could promote the change of M2 type to M1 type TAMs, exerting anti-non-small cell lung cancer (anti-NSCLC) cell effects and resulting in CD8+ T cell infiltration into the TME (29).